InsidersTradesSigma
AI
Alcon Inc. Stock: price and management transactions · Switzerland · SIX SER
Follow the Alcon Inc. share price and the full insider trade history of the company, a listed equity based in Switzerland. Shares trade on CH CH, under the oversight of SIX SER. Operating in the Healthcare & Pharma sector, Alcon Inc. has published 39 public disclosures. Market capitalisation: €26.8bn. The latest transaction was disclosed on 7 May 2026 (Purchase). Among the most active insiders: Anonymous (Non-executive member of the board of directors). The full history is free.
39
Insider Decl.
0
Thresholds
€4m
22 ops.
Buy Volume
€22m
17 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Alcon Inc. Buy (bullish), based on 17 analysts. Average price target: CHF 76.56.
24Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 6,381 of 26,127 companies
64.4
score / 100
Value62
Quality67
FCF yld6.1%
Earn yld3.7%
EV/EBITDA10.0x
ROE3.7%
Gross mgn55%
Net mgn9.4%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 7 May 2026
Declarations39 total
●
Anonymous (a non-executive member of the board of directors)
a non-executive member of the board of directorsExecutives(filed)
3,000 shares@ CHF 51.140.0007% mcap25.6% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q5700083
Ideal exit: 1 Feb 2027 (T+270)
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
3,000 shares@ CHF 51.1350.0007% mcap5.4% of flowSIX:T1Q5700083
Ideal exit: 1 Feb 2027 (T+270)
●
Anonymous (a non-executive member of the board of directors)
a non-executive member of the board of directorsExecutives(filed)
1 shares@ CHF 172,500.000.0008% mcap28.7% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4U00023
Ideal exit: 25 Jan 2027 (T+270)
●
Anonymous (a non-executive member of the board of directors)
a non-executive member of the board of directorsExecutives(filed)
1 shares@ CHF 85,000.000.0004% mcap14.1% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4U00049
Ideal exit: 25 Jan 2027 (T+270)
●
Anonymous (a non-executive member of the board of directors)
a non-executive member of the board of directorsExecutives(filed)
1 shares@ CHF 190,000.000.0008% mcap31.6% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4U00031
Ideal exit: 25 Jan 2027 (T+270)
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
1 shares@ CHF 85,000.000.0004% mcap3.0% of flowSIX:T1Q4U00049
Ideal exit: 25 Jan 2027 (T+270)
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
1 shares@ CHF 190,000.000.0008% mcap6.7% of flowSIX:T1Q4U00031
Ideal exit: 25 Jan 2027 (T+270)
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
1 shares@ CHF 172,500.000.0008% mcap6.1% of flowSIX:T1Q4U00023
Ideal exit: 25 Jan 2027 (T+270)
●
Anonymous (Executive member of the board of directors / member of senior management)
Executive member of the board of directors / member of senior managementExecutives
15,000 shares@ CHF 66.9735.0% of flowSIX:T1Q2Q00074
●
Anonymous (Executive member of the board of directors / member of senior management)
Executive member of the board of directors / member of senior managementExecutives
2,412 shares@ CHF 67.2420.8% of flowSIX:T1Q2Q00066
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
10,000 shares@ CHF 63.658421.9% of flowSIX:T1P8S00045
Ideal exit: 25 May 2026 (T+270)
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
1,560 shares@ CHF 63.72133.4% of flowSIX:T1P8L000G5
Ideal exit: 18 May 2026 (T+270)
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
1,000 shares@ CHF 62.962.2% of flowSIX:T1P8L00099
Ideal exit: 18 May 2026 (T+270)
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
1,250 shares@ CHF 63.4182.7% of flowSIX:T1P8L00032
Ideal exit: 18 May 2026 (T+270)
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
2,000 shares@ CHF 64.804.4% of flowSIX:T1P8L00024
Ideal exit: 18 May 2026 (T+270)
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
3,000 shares@ CHF 73.007.5% of flowSIX:T1P5F00097
Ideal exit: 9 Feb 2026 (T+270)
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
1 shares@ CHF 150,000.005.2% of flowSIX:T1P5600038
Ideal exit: 31 Jan 2026 (T+270)
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
1 shares@ CHF 147,500.005.1% of flowSIX:T1P5600046
Ideal exit: 31 Jan 2026 (T+270)
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
1 shares@ CHF 167,500.005.8% of flowSIX:T1P5600053
Ideal exit: 31 Jan 2026 (T+270)
●
Anonymous (Executive member of the board of directors / member of senior management)
Executive member of the board of directors / member of senior managementExecutives
12,600 shares@ CHF 83.97155.1% of flowSIX:T1P33000F8
●
Anonymous (Executive member of the board of directors / member of senior management)
Executive member of the board of directors / member of senior managementExecutives
20,000 shares@ CHF 82.96228.1% of flowSIX:T1P2S00063
●
Anonymous (Executive member of the board of directors / member of senior management)
Executive member of the board of directors / member of senior managementExecutives
9,000 shares@ CHF 82.43823.6% of flowSIX:T1P2R00057
●
Anonymous (Executive member of the board of directors / member of senior management)
Executive member of the board of directors / member of senior managementExecutives
10,000 shares@ CHF 85.2644.1% of flowSIX:T1O9C00030
●
Anonymous (Executive member of the board of directors / member of senior management)
Executive member of the board of directors / member of senior managementExecutives
112,182 shares@ CHF 85.535946.3% of flowSIX:T1O9C00063
●
Anonymous (Executive member of the board of directors / member of senior management)
Executive member of the board of directors / member of senior managementExecutives
4,622 shares@ CHF 81.87671.8% of flowSIX:T1O9900049
25 of 39 declarations
About Alcon Inc.
Alcon Inc. is a global eye-care company listed on the SIX Swiss Exchange (SMI/SPI) and domiciled in Switzerland, with its global headquarters in Geneva. The company is one of the world’s leading ophthalmology names, with a strong position in both surgical eye care and vision care. Its roots go back to 1945, when it was founded in Fort Worth, Texas, by two pharmacists. After decades as part of Novartis, Alcon was separated into an independent public company in 2019. Alcon’s business model is built around two core segments: Surgical and Vision Care. The Surgical division includes equipment, consumables and systems used in cataract, refractive and vitreoretinal procedures, as well as phacoemulsification platforms, lasers, implants and related surgical instruments. The Vision Care segment covers contact lenses, lens care products, artificial tears and other eye-health and comfort products. This dual structure gives Alcon exposure to both high-innovation medical devices and recurring consumer-oriented eye-care demand. From a competitive standpoint, Alcon holds a solid position in a highly specialized global market that features high barriers to entry, meaningful regulatory hurdles and a constant need for clinical innovation. The company benefits from a large installed base of surgical equipment, a recognized brand and a broad portfolio spanning the eye-care continuum. It is commonly regarded as the global leader in eye-care devices, with commercial reach across North America, Europe, Asia-Pacific and emerging markets, supported by R&D, manufacturing and distribution capabilities in multiple geographies. Key products and solutions include cataract surgery platforms, surgical visualization and aspiration systems, Air Optix and DAILIES contact lenses, as well as products addressing dry eye and everyday visual comfort. Alcon regularly highlights new product launches and technological advances, which support its defensive profile and its ability to refresh the portfolio over time. Recent developments have centered on innovation and strategic M&A. In 2025, Alcon announced new product launches and disclosed acquisition activity, including LENSAR and an amended agreement to acquire STAAR Surgical, strengthening its position in refractive surgery and laser-enabled vision correction solutions. For investors, Alcon offers a quality healthcare exposure, global diversification and a long-term growth profile supported by demographic aging and structural demand for eye care.
